November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
A 2 part update on AI-RANO published on The Lancet Oncology
Nov 12, 2024, 16:05

A 2 part update on AI-RANO published on The Lancet Oncology

Vivek Subbiah posted on LinkedIn about recent paper by Javier E Villanueva-Meyer et al., titled “Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements” published on The Lancet Oncology.

Authors: Javier E Villanueva-Meyer, Spyridon Bakas, Pallavi Tiwari, Janine M Lupo, Evan Calabrese, Christos Davatzikos, Wenya Linda Bi, Marwa Ismail, Hamed Akbari, Philipp Lohmann, Thomas C Booth, Benedikt Wiestler, Hugo J W L Aerts, Ghulam Rasool, Joerg C Tonn, Martha Nowosielski, Rajan Jain, Rivka R Colen, Sarthak Pati, Ujjwal Baid, Philipp Vollmuth, David Macdonald, Michael A Vogelbaum, Susan M Chang, Raymond Y Huang, Norbert Galldiks.

A 2 part update on AI-RANO published on The Lancet Oncology

“Nice update published in Lancet Oncology as a 2 part review

Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements”

Vivek Subbiah also shared about part 2 of this paper by Spyridon Bakas et al., titled “Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice” published on The Lancet Oncology.

Authors: Spyridon Bakas, Philipp Vollmuth, Norbert Galldiks, Thomas C Booth, Hugo J W L Aerts, Wenya Linda Bi, Benedikt Wiestler, Pallavi Tiwari, Sarthak Pati, Ujjwal Baid, Evan Calabrese, Philipp Lohmann, Martha Nowosielski, Rajan Jain, Rivka Colen, Marwa Ismail, Ghulam Rasool, Janine M Lupo, Hamed Akbari, Joerg C Tonn, David Macdonald, Michael Vogelbaum, Susan M Chang, Christos Davatzikos, Javier E Villanueva-Meyer, Raymond Y Huang.

A 2 part update on AI-RANO published on The Lancet Oncology

“Part 2 of a two part update published in Lancet Oncology

Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice.”

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.